Novavax (NVAX) Expected to Post Earnings on Thursday

Key Points

• Novavax is expected to report Q3 2026 results before market open on November 5. Analysts forecast a loss of $0.35 per share and revenue of approximately $54.2 million.
• In the prior quarter, Novavax beat EPS and revenue estimates, but revenue fell 76.2% year over year to $56.7 million and the company posted a negative net margin of 59.87%.
• Analyst sentiment remains mixed, with an overall “Hold” rating and an average price target of $12.33, compared with the stock’s recent price of $10.32.

Novavax (NASDAQ:NVAX - Get Free Report) is projected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Novavax to post earnings of ($0.3459) per share and revenue of $54.20 million for the quarter. Individuals are encouraged to explore the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Novavax (NASDAQ:NVAX - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.38) by $0.06. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. The business had revenue of $56.70 million during the quarter, compared to the consensus estimate of $52.51 million. During the same quarter last year, the firm posted $0.62 EPS. The business's revenue was down 76.2% compared to the same quarter last year. On average, analysts expect Novavax to post ($0.38) EPS for the current fiscal year and $0.14 EPS for the next fiscal year.

Novavax Stock Up 3.0%

Shares of NASDAQ NVAX opened at $10.32 on Thursday. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -6.79 and a beta of 2.44. Novavax has a 52 week low of $6.20 and a 52 week high of $13.39. The firm has a 50-day moving average price of $10.39 and a 200 day moving average price of $9.27.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on NVAX shares. Citigroup reaffirmed a "sell" rating and issued a $8.00 target price (up from $7.00) on shares of Novavax in a report on Thursday, October 15th. Zacks Research downgraded Novavax from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 6th. Wall Street Zen raised Novavax from a "sell" rating to a "hold" rating in a report on Saturday, September 12th. Weiss Ratings reiterated a "sell (d)" rating on shares of Novavax in a research report on Tuesday, August 4th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Novavax in a research report on Tuesday. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $12.33.

Novavax Company Profile

Novavax, Inc is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.

Novavax's principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.

Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.